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ABSTRACT
Purpose. Tyrosine 1248 is one of the autophosphory-
lation sites of human epidermal growth factor recep-
tor (HER)-2. We determined the prognostic value
of the expression level of tyrosine 1248 –phosphory-
lated HER-2 (pHER-2) in patients with HER-2 pri-
mary breast cancer using a reverse-phase protein
array.
Patients and Methods. The optimal cutoff value of
pHER-2 for segregating disease-free survival (DFS) was
determined by receiver operating characteristic (ROC)
curve analysis. Five-year DFS for pHER-2 expression
level was estimated with the Kaplan-Meier method us-
ing both derivation (n  162) and validation (n  227)
cohorts.
Results. Of the 162 patients in the derivation cohort,
26 had high HER-2 expression levels. The area under
the ROC curve for pHER-2 level and DFS was 0.662.
Nineteen of the 162 patients (11.7%) had high pHER-2
expression levels (pHER-2high); 143 patients (88.3%)
had low pHER-2 expression levels (pHER-2low). Among
the 26 patients with high HER-2 expression levels, the
17 pHER-2high patients had a significantly lower 5-year
DFS rate than the nine pHER-2low patients (23.5% ver-
sus 77.8%). On multivariate analysis, only pHER-2high
independently predicted DFS in the Cox proportional
hazards model. In the validation cohort, among 61 pa-
tients with high HER-2 expression, the difference in
5-year DFS rates between pHER-2high (n  7) and
pHER-2low (n 54) patients was marginal (57.1% ver-
sus 81.5%).
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Conclusion. In patients with HER-2 primary breast
cancer, pHER-2high patients had a lower 5-year DFS
rate than pHER-2low patients. Quantification of
pHER-2 expression level may provide prognostic infor-
mation beyond the current standard HER-2 status. The
Oncologist 2011;16:956–965
INTRODUCTION
Human epidermal growth factor receptor (HER)-2 is over-
expressed or amplified in approximately 15%–20% of
breast cancers, and HER-2 expression is a prognostic factor
for breast cancer [1–3]. In patients with HER-2 breast can-
cer, the combination of standard chemotherapy plus trastu-
zumab, a monoclonal antibody targeting HER-2, has
resulted in higher progression-free and overall survival
rates than with standard chemotherapy alone [4–6]. How-
ever, only 30% of patients with HER-2 metastatic breast
cancer respond to trastuzumab [7–19].
Phosphorylation of HER-2 induces downstream intra-
cellular signaling and activates genes related to cell growth.
HER-2 has several autophosphorylation sites, including ty-
rosine (Tyr)1248, 1221/1222, and 877, and others, and
phosphorylation at these sites may reflect HER-2 activity
[20–30]. To date, the most widely studied phosphorylation
site is Tyr1248, the only site for which there is an antibody
established to be stable in human tissues [25, 26, 28–30].
Some studies have reported that Tyr1248-phosphorylated
HER-2 (pHER-2) assessed by immunohistochemistry
(IHC) is related to resistance to trastuzumab and poor prog-
nosis in patients with HER-2 breast cancer [25, 26, 28–
30]. However, we are aware of no studies to date that have
identified specific levels of pHER-2 that can be used as cut-
offs to stratify patients with respect to prognosis. The abil-
ity to stratify the prognosis of patients with HER-2 breast
cancer on the basis of pHER-2 expression level could allow
testing of novel agents targeting pHER-2.
Reverse-phase protein array (RPPA) is an antibody-
based quantitative assay that has advantages over IHC in as-
sessing the phosphorylation of proteins. Although IHC
provides information about the presence or absence of pro-
tein phosphorylation, it does not permit precise quantifica-
tion of the amount of phosphorylated protein. RPPA, in
contrast, permits, with just a small amount of material,
quantification of the expression level and modification
(e.g., phosphorylation) of proteins as a continuous value for
a large number of patients.
We hypothesized that the HER-2 expression level by
RPPA is concordant with HER-2 status by IHC or fluores-
cence in situ hybridization (FISH) and that in patients with
HER-2 breast cancer, high expression of pHER-2 by
RPPA is associated with shorter disease-free survival
(DFS) than low expression of pHER-2 by RPPA. We eval-
uated this hypothesis in a large derivation set and in a sep-
arate validation set from another institution.
MATERIALS AND METHODS
Human Tumor Samples
Tumorsamples from162patientswithprimary invasiveductalor
invasive lobular breast carcinoma surgically resected from June
1992 to March 2007 were obtained from the breast tissue frozen
tumor bank at The University of Texas MD Anderson Cancer
Center. Patients with ductal carcinoma in situ, metaplastic carci-
noma, or sarcoma were excluded. Samples were not collected
consecutively but mainly based on tumor availability. No patients
received a HER-2–targeting agent for pre- or postoperative che-
motherapy because the use of trastuzumab for adjuvant therapy
wasnotapprovedbytheU.S.FoodandDrugAdministrationuntil
November 2006. Clinical data were collected from the Breast
Cancer Management System database of MD Anderson. A vali-
dation set of tumor samples from 227 postmenopausal patients
who had primary invasive ductal or invasive lobular breast carci-
noma surgically resected from August 1988 to December 1998
and who received hormone therapy only was obtained from col-
laborators at the Hospital Clínico Universitario de Valencia,
Spain. Samples were collected based on tumor availability. The
validation set was used to validate the findings from the MD An-
derson population. All specimens were collected under institu-
tional review board approval.
Pathology Methods
Samples were considered positive for estrogen receptor
(ER) or progesterone receptor (PR) if10% of the cells had
nuclear staining for the receptor. In the derivation set,
HER-2 status was evaluated by IHC or FISH. HER-2 pos-
itivity was defined as 3 receptor overexpression on IHC
staining or gene amplification on FISH, defined as a gene
copy–chromosome enumeration probe 17 ratio2.0. In the
validation set, HER-2 status by IHC or FISH was not avail-
able. Therefore, to stratify these patients with respect to
HER-2 level, we used the cutoff value of HER-2 positivity
that was developed using RPPA data from the derivation set
(see Statistical Methods below).
RPPA
RPPA analysis was performed in our laboratory as described pre-
viously [31–35]. Briefly, lysis buffer was used to lyse frozen tu-
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mors by homogenization. Tumor lysates were normalized to 1
g/l concentration using a bicinchoninic acid assay. The lysates
were then boiled with 1% sodium dodecyl sulfate, and the super-
natants were manually diluted in six or eight twofold serial dilu-
tions with lysis buffer. From the serial dilutions, an Aushon
Biosystems 2470 arrayer was used to create sample arrays on ni-
trocellulose-coated FAST™ slides (Schleicher & Schuell Bio-
Science, Inc.,Keene,NH).Eachslidewasprobedwithavalidated
primary HER-2 and pHER-2 antibody, and the signal was ampli-
fied with a DakoCytomation catalyzed system (Dako, Glostrup,
Denmark). The slides were analyzed and quantitated with the use
of MicroVigene software (VigeneTech Inc., Carlisle, MA). The
levels of HER-2 and pHER-2 in each sample were expressed as
log-mean centered as previously described. We used the p-Neu
2A (PN2A) antibody to detect phosphorylation of Tyr1248. This
antibodyspecifically recognizesphosphorylationof themajorau-
tophosphorylation site Tyr1248 and has no crossreactivity with
other related receptors, including epidermal growth factor recep-
tor, HER-3, and HER-4, or unphosphorylated HER-2, as demon-
strated in a previous study [36]. Antibodies for other
phosphorylation sites of HER-2 have not been validated for
RPPA analysis. Therefore, we determined Tyr1248 phosphory-
lation only.
Statistical Methods
Correlations between the expression levels of HER-2 and
pHER-2 in tumors and the 5-year DFS rate were determined
using both the derivation (n  162) and validation (n 
227) cohorts. Receiver operating characteristic (ROC)
curve analyses were used to determine the optimal cutoff
values for segregating 5-year DFS. The concordance of
HER-2 expression level by RPPA and HER-2 status by IHC
or FISH was analyzed using Cohen’s  coefficient.
Baseline patient characteristics by HER-2 and pHER-2
expression are summarized with medians and ranges for
age and follow-up time and with frequencies and percent-
ages for all other characteristics. Time to recurrence was
measured from the date of diagnosis to the date of first de-
tection of local disease recurrence or distant metastasis or to
the date of last follow-up. Because the at-risk proportion of
patients became very small at 5 years and because most of
the recurrences had occurred by then, the follow-up time
was truncated at 5 years. Time to recurrence was estimated
with the Kaplan–Meier method and was compared between
groups using the log-rank statistic. Cox proportional haz-
ards models were fit to determine the association of
pHER-2 status and the risk for recurrence after adjustment
for other patient and disease characteristics. Each model
contained terms for age at diagnosis, menopausal status,
presence of lymph node metastasis at diagnosis, stage, hor-
mone receptor status, and receipt of pre- or postoperative
chemotherapy. p-values.05 were considered statistically
significant. All statistical analyses were done using SPSS
version 17 (SPSS Inc., Chicago, IL).
RESULTS
Clinicopathologic Characteristics of the
Derivation Cohort
The clinicopathologic characteristics of the derivation co-
hort are listed in Table 1. The median age was 53 years
(range, 27–83 years). The 162 breast cancers included 72
cancers (44.4%) that were hormone receptor positive (ER
or PR) and 26 cancers (16.0%) that were positive for HER-2
by IHC or FISH. At 5 years of follow-up, 37 patients
(22.8%) in the derivation cohort had died.
Concordance Between HER-2 Expression Level
by RPPA and HER-2 Status by IHC or FISH
The area under the ROC curve for analysis of the relation-
ship between HER-2 expression level by RPPA and HER-2
status by IHC and/or FISH was 0.873. An optimal cutoff
value of HER-2 expression level was developed at 0.272.
Using this optimal cutoff value, 26 (16.0%) of the 162 pa-
tients in the derivation cohort had high HER-2 expression
levels (HER-2 breast cancer). HER-2 expression level by
RPPA was concordant with HER-2 status by IHC or FISH
( coefficient p .679; Fisher’s exact test p .000; sensi-
tivity, 73.8%; specificity, 94.9%).
Prognostic Value of HER-2 in the Entire
Derivation Cohort
The prognostic role of HER-2 expression level by RPPA
was determined using the aforementioned cutoff values. In
the derivation set, the 5-year DFS rate was significantly
lower in the 26 patients with a high HER-2 expression level
than in the 136 patients with a low HER-2 expression level
(42.3% versus 72.1%; p .010) (Fig. 1).
Optimal Cutoff Value of pHER-2 Expression
The area under the ROC curve for the analysis of the rela-
tionship between the pHER-2 expression level and 5-year
DFS rate in the 26 patients with breast cancer with a high
HER-2 expression level was 0.662. An optimal cutoff value
of pHER-2 expression level was developed at 1.536. Using
this optimal cutoff value, 19 (11.7%) of the 162 patients had
a high pHER-2 expression level and 143 (88.3%) had a low
pHER-2 expression level (Table 2). In the 26 patients with
a high HER-2 expression level, 17 (65.3%) had a high
pHER-2 expression level and nine (34.7%) had a low
pHER-2 expression level (Table 2).
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Prognostic Value of pHER-2 in the Entire
Derivation Cohort
The prognostic role of the pHER-2 expression level was de-
termined using the aforementioned cutoff values in a log-
rank analysis. In the derivation cohort, patients with a high
pHER-2 expression level had a significantly lower 5-year
DFS rate than patients with a low pHER-2 expression level
(p .000) (Fig. 2A).
PROGNOSTIC VALUE OF PHER-2 IN DERIVATION-
COHORT PATIENTS WITH A HIGH HER-2
EXPRESSION LEVEL
Among the 26 patients who had a high HER-2 expression
level, patients with a high pHER-2 expression level had a
significantly lower 5-year DFS rate than patients with a low
pHER-2 expression level (23.5% versus 77.8%; p  .020)
(Fig. 2B).
Figure 1. Kaplan–Meier functions of 5-year disease-free sur-
vival by HER-2 status in the derivation cohort.
Abbreviation: HER-2, human epidermal growth factor re-
ceptor 2.
Table 1. Patient characteristics
Derivation set Validation set
Characteristic (n 162) (n 227)
Median age (range) 53 (27–83) yrs 68.8 (30–80) yrs
Median follow-up time (range) 44.8 (1.4–236.1) mos 83.3 (1.5–196.5) mos
ER and/or PR status
Positive 72 (44.4%) 192 (84.6%)
Negative 90 (55.6%) 35 (15.4%)
HER-2/neu status
Positive (3, 2/FISH) 26 (16.0%) NA
Negative (0, 1, 2/FISH) 136 (84.0%) NA
Lymph node metastasis status
Positive 87 (53.7%) 95 (41.9%)
Negative 73 (45.1%) 129 (56.8%)
NA 2 (1.2%) 3 (1.3%)
Pathologic stage
0 2 (1.2%) 0 (0%)
I 26 (16.0%) 55 (24.2%)
II 90 (55.6%) 136 (59.9%)
III 42 (26.0%) 23 (10.1%)
NA 2 (1.2%) 13 (5.7%)
Treatment
Chemotherapy 129 (74.6%) 0 (0%)
Hormone therapy 58 (35.8%) 227 (100%)
HER-2–targeting agent 0 (0%) 0 (0%)
Survival status at last follow-up
Alive 125 (77.2%) 76 (33.5%)
Dead 37 (22.8%) 151 (66.5%)
Data are n of patients (%) unless otherwise specified.
Abbreviations: ER, estrogen receptor; FISH, fluorescence in situ hybridization; HER-2, human epidermal growth factor
receptor 2; NA, not available; PR, progesterone receptor.
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On univariate analysis, other factors, including age,
menopausal status, lymph node status, pathological
stage, hormone receptor status, and pre- or postoperative
chemotherapy, were not associated with 5-year DFS (Ta-
ble 3). On multivariate analysis, only the pHER-2 ex-
pression level was an independent prognostic factor
(hazard ratio, 5.94; 95% confidence interval, 1.057–
33.387; p  .043) (Table 3).
Clinicopathologic Characteristics of the
Validation Cohort
Clinicopathologic characteristics of the validation cohort
are listed in Table 1. The median age was 68.8 years (range,
30–80 years). The 227 breast cancers included 192 cancers
(84.6%) that were hormone receptor positive. All patients
received hormone therapy; none received chemotherapy.
Ninety-five of the patients (41.9%) had lymph node metas-
Table 2. Expression level of tyrosine 1248–phosphorylated human epidermal growth factor receptor 2 (pHER-2)
Derivation set Validation set
In all patients (n 162) (n 227)
High pHER-2 expression 19 (11.7%) 7 (3.2%)
Low pHER-2 expression 143 (88.3%) 220 (96.8%)
In patients with high HER-2 expression (n 26) (n 61)
High pHER-2 expression level 17 (65.3%) 7 (11.5%)
Low pHER-2 expression level 9 (34.7%) 54 (88.5%)
Data are n of patients (%).
Figure 2. Kaplan–Meier functions of 5-year disease-free survival by Tyr1248-phosphorylated HER-2 (pHER-2) status in the
entire derivation cohort (A), derivation-cohort patients with high HER-2 expression (B), the entire validation cohort (C), and
validation-cohort patients with high HER-2 expression (D).
Abbreviation: HER-2, human epidermal growth factor receptor 2.
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tases; 55 (24.2%) had stage I, 136 (59.9%) had stage II, and
23 (10.1%) had stage III disease.
Prognostic Value of pHER-2 in the Validation
Cohort
The reproducibility of the prognostic value of pHER-2 by
RPPA was determined in the validation cohort. In this co-
hort, HER-2 status was not available by IHC or FISH.
Therefore, we applied a cutoff value of HER-2 positivity of
0.272, which was estimated using the derivation set. Using
this cutoff value, 61 (26.9%) of the 227 patients in the val-
idation cohort had a high HER-2 expression level by RPPA
(Table 2).
Patients with a high pHER-2 expression level (n  7)
had a significantly lower 5-year DFS rate than patients with
a low pHER-2 expression level (n  220; p  .024) (Fig.
2C). In the 61 patients with a high HER-2 expression level,
there was a trend toward a lower 5-year DFS rate in patients
with a high pHER-2 expression level (n  7) than in pa-
tients with a low pHER-2 expression level (n 54) (57.1%
versus 81.5%; p  .077) (Fig. 2D). Only lymph node me-
tastasis was an independent prognostic factor on multivar-
iate analysis (hazard ratio, 0.121; 95% confidence interval,
0.015–0.967; p 0.046) (Table 4).
DISCUSSION
We have provided the first clinical evidence that the expres-
sion level of pHER-2 by RPPA, which can quantify phos-
phorylated proteins, may have a prognostic role in patients
with HER-2 breast cancer. In the derivation cohort,
among patients with HER-2 breast cancer, the expression
level of pHER-2 was the only factor associated with the
5-year DFS rate on both univariate and multivariate analy-
sis. There was a similar trend in the validation cohort using
data from another institution. These results indicate that
pHER-2 expression level may have potential as an addi-
tional prognostic marker in patients with HER-2 breast
cancer.
The prognostic and predictive roles of pHER-2 in breast can-
cer patients have previously been reported (Table 5) [20, 23–28,
30]. Our results concur with those of previous studies, although in
most previous studies phosphorylated HER-2 was examined us-
ing IHC with PN2A [22, 29, 30], which is an antibody against
HER-2 with phosphorylation at Tyr1248. Tyr1248 is one of the
C-terminal sites that are phosphorylated before downstream sig-
naling occurs [21, 37–39]. Tyr1248 phosphorylation contributes
to induceactivationof theHER-2oncoprotein [20–29].Frogneet
al. [23] reported the clinical relevance of Tyr1221/1222-phos-
phorylated HER-2, because pHER-2 using the antibody against
Tyr1248 was only weakly stained in their positive control. Other
phosphorylation sites of HER-2 (Tyr877, Tyr1005, Tyr1127,
Tyr1144, Tyr1201, Tyr1226/1227, and Tyr1253) have not been
examined inhumanspecimens,and theiraccuraciesandprognos-
tic values have not been shown [21, 40, 41].
In this study, we assessed the expression level of pHER-2
by RPPA, which permits quantification of phosphorylated
proteins [31–35]. RPPA is a highly reliable, reproducible, and
high-throughput system for quantitative proteomic analysis of
a large number of protein expression and protein activation
sites [31, 32, 35, 42]. Expression levels of proteins by RPPA
have been confirmed to be correlated with the results of tradi-
tional Western blotting [35]. In addition, the concurrent com-
Table 3. Predictors of 5-year disease-free survival on univariate and multivariate analysis in a Cox regression analysis for
the derivation cohort
Characteristic
Univariate analysis Multivariate analysis
Cox p HR
95% CLs
Cox p HR
95% CLs
Lower Upper Lower Upper
Age, yrs (50 versus 50) .450 1.5 0.52 4.4 – – – –
Menopausal status (pre versus post) .810 0.88 0.31 2.55 – – – –
Lymph node metastases (positive versus negative) .300 2.0 0.54 7.1 . 991 1.01 0.17 6.07
Stage I (versus II) .896 0.87 0.11 7.1 .783 1.54 0.07 32.70
Stage I (versus III) .551 1.91 0.23 15.9 .842 1.36 0.07 28.12
Hormone receptor status (positive versus
negative)
.250 2.0 0.62 6.4 .365 1.85 0.49 6.94
Pre-/postoperative chemotherapy (received versus
not received)
.340 0.53 0.15 1.9 .393 0.46 0.08 2.74
pHER-2 (high versus low) .024 5.7 1.25 25.7 .043 5.94 1.06 33.39
Abbreviations: CL, confidence limit; HR, hazard ratio; pHER-2, tyrosine 1248–phosphorylated human epidermal growth
factor receptor 2.
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parison of a large number of samples, which RPPA makes
possible, can reduce experimental bias [32, 33, 35]. RPPA also
has the advantage of permitting objective assessment of the
expression levels of proteins because they are shown as con-
tinuous values. These characteristics of RPPA allowed us to
use the technique to develop optimal cutoff values of protein
expression for each analysis. RPPA may identify optimal mo-
lecular markers for the detection of response to treatment and
may have potential for developing novel agents targeting
pHER-2 and for therapeutic monitoring. In the past, issues re-
lated to fixation and stability of proteins were a concern with
RPPA. However, recent advances in technology have proven
the reproducibility and high sensitivity of RPPA [31–33, 35].
We previously assessed the technical utility of RPPA analysis
Table 4. Predictors of 5-year disease-free survival on univariate and multivariate analysis in a Cox regression analysis for
the validation cohort
Characteristic
Univariate analysis Multivariate analysis
Cox p HR
95% CLs
Cox p HR
95% CLs
Lower Upper Lower Upper
Age, yrs (50 versus 50) .550 0.045 0.000 1168.33 – – – –
Lymph node metastases (positive
versus negative)
.003 0.100 0.022 0.450 .046 0.121 0.015 0.967
Stage I (versus II) .027 .083 .009 0.749 .764 0.632 0.032 12.611
Stage I (versus III) .101 0.364 0.109 1.217 .444 0.608 0.169 2.179
Hormone receptor status (positive versus
negative)
.971 0.963 0.125 7.412 – – – –
pHER-2 (high versus low) .092 0.328 0.090 1.201 .592 0.687 0.174 2.713
Abbreviation: CL, confidence limit; HR, hazard ratio; pHER-2, tyrosine 1248–phosphorylated human epidermal growth
factor receptor 2.
Table 5. Previous studies of pHER-2 as a prognostic or predictive factor
Study
Method of
assessing
pHER-2
n of
patients
n of patients with pHER-2
n of patients (%)a
Outcome
Tyrosine
phosphorylation
site(s)
HER-2
primary
tumor
HER-2
primary
tumor
Hayashi et al. (present study) RPPAa 396 24/33b (73) 2/136b (1) DFS 1248
(7/61)c (11) (0/166)c (0)
Cicenas et al. [20] CLISA 70 27/40 (68) 8/30 (29) DFS, OS 1248
Thor et al. [29] IHC 307 37/307 (12) NA NA DFS, DSS 1248
DiGiovanna et al. [30] IHC 306 37/306 (12) NA NA DFS, DSS 1248
Hudelist et al. [25] IHC 62 12/54 (22) 3/8 (38) PFS, OS 1248
Hudelist et al. [26] IHC 46 9/46 (20) NA NA PFS, OS 1248
Singer et al. [28] IHC 360 7/12 (58) 2/348 (1) RFS, DFS, OS 1248
Giuliani et al. [24] IHC 100 15/100 (15) NA NA RR 1248
Modi et al. [27] IHC 110 7/24 (29) 4/86 (5) RR 1248
Frogne et al. [23] IHC 268 15/22 (68) 23/242 (10) DFS, OS 1221/1222
aPositive positive by IHC or CLISA or high expression level by RPPA; negative negative by IHC or CLISA or low
expression level by RPPA.
bDerivation cohort group.
cValidation cohort group.
Abbreviations: CLISA, chemiluminescence-linked immunoassay; DFS, disease-free survival; DSS, disease-specific
survival; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; NA, not assessed; OS, overall survival;
PFS, progression-free survival; pHER-2, phosphorylated human epidermal growth factor receptor 2; RFS, relapse-free
survival; RPPA, reverse-phase protein lysate microarray; RR, response rate.
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and confirmed the stability of pHER-2 and other proteins in
frozen samples within 24 hours after sample collection for
RPPA analysis [43]. We also checked the reproducibility of
RPPA by validating the results of our initial, derivation-set
analysis with an analysis of samples from a different institu-
tion.
Our comparison of RPPA findings and findings from
traditional pathologic analysis, including IHC and FISH,
indicated that expression levels of HER-2 by RPPA were
remarkably concordant with the standard HER-2 status de-
termined by traditional pathologic analysis. On the basis of
this reliability, we were able to justify the optimal cutoff
values related to the 5-year DFS rate that were developed
using the ROC curve analysis.
In previous studies, pHER-2 was found in 12%–68% of
HER-2 patients [31–35]. Our study showed high pHER-2 ex-
pression levels in 65.3% of the patients with a high HER-2 ex-
pression level in thederivationcohort and in11.5%of thepatients
with a high HER-2 expression level in the validation cohort. Al-
though both rates of high expression of pHER-2 are within the
range of rates reported in previous studies (Table 4), the rate of
high expression of pHER-2 was lower in the validation cohort.
This lower rate in the validation cohort may be explained by dif-
ferences in other clinicopathologic characteristics between the
derivation and validation cohorts—specifically, all the patients in
the validation cohort were postmenopausal, most of the patients
were hormone receptor positive, and all the patients received hor-
mone therapy but not chemotherapy. Therefore, the number of
pHER-2 patients in the validation cohort was small, and the
prognostic role of pHER-2 was statistically marginal in the vali-
dation cohort despite the significance proven with multivariate
analysis in the derivation cohort.
In this study, none of the patients with HER-2 breast cancer
received any HER-2–targeting agent. Thus, we were able to as-
sess the prognostic significance of pHER-2 without interference
by a HER-2–targeting agent. Assessment of the correlation be-
tween the pHER-2 expression level and the effect of HER-2–
targeting agents is a necessary next step. Furthermore, recently,
several mechanisms have been revealed for resistance to trastu-
zumab [10–19]. Phosphatase and tension homolog deleted on
chromosome 10 (PTEN) suppresses the phosphatidylinositol-3-
kinase (PI3K)/Akt pathway. Activation of the PI3K pathway by
PIK3CA mutations or low PTEN expression has been associated
withapoor response to trastuzumabandpoorprognosisafter tras-
tuzumab therapy[10–13].Assessmentof thecorrelationbetween
phosphorylation of HER-2 and activation of these downstream
pathways is also needed.
A limitation of this study is that, if the normalization pro-
cess for the RPPA dataset changes, the optimal cutoff values
for each dataset will change as well. If our optimal cutoff val-
ues of HER-2 and pHER-2 are used with other datasets, the
normalization process needs to be the same as the one used in
our study.
In summary, in HER-2 breast cancer patients, high ex-
pression of pHER-2 was associated with a lower 5-year DFS
rate than with low expression of pHER-2 in the derivation co-
hort, and a similar trend was observed in the validation cohort.
High expression of pHER-2 was rare in HER-2 breast cancer
patients. Quantification of the expression level of pHER-2
may provide further prognostic information in HER-2 breast
cancer patients in addition to the information gained from the
current standard pathologic studies. Definitive prospective
studies are warranted to further confirm this relationship.
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